GLP1R and type 2 diabetes mellitus: Retatrutide also shows great potential for treating T2D– in the phase 2 trial, it showed superior efficacy to dulaglutide 1.5 mg, a widely used GLP-1 RA with proven cardiovascular benefits, in reducing HbA1c and bodyweight.